Lytics before PCI: ASSENT Denied

Lytics before PCI: ASSENT Denied

0:00

Frans van der Werf Near-complete data from the ASSENT-4-PCI trial investigating facilitated PCI (combining both thrombolysis and primary PCI after acute myocardial infarction) has found that PCI alone

Frans van der Werf

Near-complete data from the ASSENT-4-PCI trial investigating facilitated PCI (combining both thrombolysis and primary PCI after acute myocardial infarction) has found that PCI alone is a better choice.Frans van der Werffrom the University of Leuven in Belgium.

Click here for all the interviews from AHA 2005

Related Episodes

Audio Journal of Oncology Volume 16 Number 8

Audio Journal of Oncology Volume 16 Number 8

Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F

Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro

ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up

Jack Cuzick JACK CUZICK, Wolfson Institute of Preventive Medicine, London New data from the ATAC trial, which is testing anastrozole and tamoxifen in early breast cancer, have demonstrated the continu